LGI3 抗体 (AA 310-338)
This anti-LGI3 antibody is a 兔 多克隆 antibody detecting LGI3 in WB. Suitable for 人. This Primary Antibody has been cited in 3+ publications.
1 image
(3 references)Quick Overview for LGI3 抗体 (AA 310-338) (ABIN1881494)
抗原
See all LGI3 抗体
LGI3
(Leucine-Rich Repeat LGI Family, Member 3 (LGI3))
适用
人
宿主
兔
克隆类型
多克隆
标记
This LGI3 antibody is un-conjugated
应用范围
Western Blotting (WB)
克隆位点
RB40597
-
-
抗原表位
- AA 310-338
-
预测反应
- Pr, M
-
纯化方法
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
免疫原
- This LGI3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 310-338 amino acids from the Central region of human LGI3.
-
亚型
- Ig Fraction
-
-
anti-Leucine-Rich Repeat LGI Family, Member 3 (LGI3) (AA 449-548) antibody
LGI3 适用: 人 WB, ELISA 宿主: 小鼠 Polyclonal unconjugated
anti-Leucine-Rich Repeat LGI Family, Member 3 (LGI3) (AA 261-548) antibodyLGI3 适用: 人 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- WB: 1:1000
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
有效期
- 6 months
-
-
-
: "Leucine-rich glioma inactivated 3 is involved in amyloid beta peptide uptake by astrocytes and endocytosis itself." in: Neuroreport, Vol. 19, Issue 12, pp. 1175-9, (2008) (PubMed).
: "The novel EPTP repeat defines a superfamily of proteins implicated in epileptic disorders." in: Trends in biochemical sciences, Vol. 27, Issue 9, pp. 441-4, (2002) (PubMed).
: "A common protein interaction domain links two recently identified epilepsy genes." in: Human molecular genetics, Vol. 11, Issue 15, pp. 1757-62, (2002) (PubMed).
-
: "Leucine-rich glioma inactivated 3 is involved in amyloid beta peptide uptake by astrocytes and endocytosis itself." in: Neuroreport, Vol. 19, Issue 12, pp. 1175-9, (2008) (PubMed).
-
-
You are here:
